6401 RESULTS
Sort By:
Do you associate technology with youth? Picture this woman doing an automated telephone assessment and think again. Modern gadgets stand poised to transform dementia research and care. Researchers are harnessing the power of computers, digital cameras, an
Last year's ice bucket challenge for amyotrophic lateral sclerosis netted $220 million in donations for ALS charities, and the 2015 challenge is off to a strong start with $100,000 from Major League Baseball. Alzforum looks at how all that money is b
The European Union is banking on big returns from nanotechnology in the fight against AD. European Union Throws Megabucks at Nanomedicine EU Consortium Applies Nanotechnology to Study AD
CRISPR Gene Editing—Poised to Revolutionize Neuroscience? Neuroscientists Probe CRISPR Transgenics and Treatment Paradigms
U.S. guidelines for assessing Alzheimer's disease (AD) neuropathology are getting a much-needed facelift. The existing ones, in place since 1997, had fallen out of step with the current understanding of AD as a disease with a long preclinical stage.
Move over, genome, transcriptome, proteome. The latest ome aims to map every metabolite linked to human health and disease. Metabolomics, although still a nascent field, offers hope for biomarkers and treatments in neurodegenerative disease. The field
Banked brain tissue enables crucial advances in the understanding and treatment of degenerative disorders. As appreciation of the many different variants of neurodegenerative disease is growing, well-preserved tissue is in more demand than ever. Are the b
Did you know that if you had a spinal tap for a cerebrospinal fluid-based Alzheimer's diagnosis in Boston, Stockholm, London, or San Diego, the readout would likely be different in each place? And different again this year and next? That's a pro
Alzforum readers who follow the science of preclinical Alzheimer's and prevention may have heard about three independent but complementary programs that together are laying the groundwork for secondary prevention trials across the spectrum of rare to
A contentious hypothesis about where and how Parkinson’s disease starts off is gaining ground as new studies provide clues in its support. Neuroanatomists Heiko Braak and Kelly Del Tredici, both at the University of Ulm in Germany, have described the dist
Have neuroscientists entered the era of the programmable brain? Thanks to optogenetics and pharmacogenetics, which let scientists switch neuronal activity on or off with light or designer drugs, scientists can now control specific subtypes of neurons in r
Are you curious about trying iPS cell lines to model the disease you care about? Intrigued but nebulous on where the field is at? Ready to grow an iPS line but not sure where to turn? Read Madolyn Rogers's four-part series to learn all about who does
In the Finnish city of Kuopio, neurosurgeons collaborate with neurophysiologists and molecular and cellular biologists to make frontal cortex, dura, intraventricular CSF, skin, fat, and other tissue from hydrocephalus patients available for research purpo
The rarest kind of Alzheimer's disease, the form that is inherited from parent to child with a cruel 50 percent likelihood, has long been marked by its untapped opportunities. Affected families have made possible both the discovery of the first three
In the absence of truly effective treatments, and in the presence of a rapidly growing, dementia-prone population of elders, it's perhaps no surprise that people are increasingly open to products claiming even the slightest hint of promise, however u
No filters selected
